{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 90 of 128', '13.5 Other events that require expedited reporting', '13.5.1 Pregnancy', 'Any pregnancy occurring during the clinical trial must be reported to LEO within 24 hours of', 'first knowledge using the (paper) Pregnancy Form (Part ] I). All pregnancies must be followed', 'up until delivery or termination and final outcome must be reported on the (paper) Pregnancy', 'Form (Part II) within 24 hours of first knowledge.', 'The completed Pregnancy Forms must be faxed or scanned and e-mailed to Global', 'Pharmacovigilance at LEO. Contact details are given in Section 13.4.1.', 'Pregnant subjects must immediately discontinue IMP permanently (Sections 10.2.1 and 10.3).', '13.6 Reporting of other events', '13.6.1 Adverse events of special interest', 'The event listed in Panel 15 is considered an adverse event of special interest in this trial and', 'will require that the investigator provides additional details to be recorded in the eCRF. An', 'adverse event of special interest may be serious (requiring expedited reporting, Section 13.4)', 'or non-serious.', 'Panel 15: Adverse event of special interest', 'Adverse event of special interest', 'Additional information to be provided', 'Eczema herpeticum', 'Skin findings:', 'Lesion type.', 'Disseminated/localised.', 'Location.', 'Present in area with visible', 'eczema/no visible eczema/present in', 'areas with and without eczema.', 'Monomorphic/polymorphic.', 'Confirmation of herpes simplex virus.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 91 of 128', '13.6.2 Overdose', 'An overdose is defined as a subject using more than double the recommended quantity of IMP', 'specified in this protocol in Section 9.2. An overdose is either accidental or intentional.', \"The term 'overdose' including a specification of why it occurred (accidental or intentional)\", 'must be documented on the AE form of the eCRF. In addition, AEs originating from an', 'overdose must be documented on a separate line. If the AE originating from the overdose', 'qualifies as an SAE, expedited reporting is required (Section 13.4).', '13.6.3 Medication error', 'Medication error refers to any unintentional error in the dispensing or administration of an', 'IMP while in the control of the investigator or subject. Broadly, medication errors fall into', '4 categories: wrong medication, wrong dose (including strength, form, concentration,', 'amount), wrong route of administration, or wrong subject.', 'The medication error category must be documented on the AE form in the eCRF. In addition,', 'AEs originating from a medication error must be documented on a separate line. If the AE', 'originating from the medication error qualifies as an SAE, expedited reporting is required', '(Section 13.4).', '13.6.4 Misuse', 'Misuse refers to situations where the IMP is intentionally and inappropriately used not in', 'accordance with the protocol.', 'The term \"misuse\\' must be documented on the AE form in the eCRF. In addition, AEs', 'originating from misuse must be documented on a separate line. If the AE originating from', 'misuse qualifies as an SAE, expedited reporting is required (Section 13.4).', '13.6.5 Abuse', 'Abuse relates to the sporadic or persistent, intentional excessive use of an IMP which is', 'accompanied by harmful physical or psychological effects.', 'The term \"abuse\\' must be documented on the AE form in the eCRF. In addition, AEs', 'originating from abuse must be documented on a separate line. If the AE originating from', 'abuse qualifies as an SAE, expedited reporting is required (Section 13.4).']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 92 of 128', '13.6.6 Aggravation of condition', 'Any clinically significant aggravation/exacerbation/worsening of any medical condition(s)', '(including the trial disease), compared to screening, must be reported as an (S)AE in', 'accordance with Sections 13.3 and 13.4.', '13.7 Follow-up for final outcome of adverse events', 'During the trial, the investigator should follow up for final outcome on all AEs (including', 'SAEs). Once a subject leaves the clinical trial, the investigator should follow up on the', 'outcome of all non-serious AEs classified as of possibly/probably relationship to the IMP for', '14 days or until the final outcome is determined, whichever comes first. SAEs must be', 'followed up until a final outcome has been established, that is, the follow-up may continue', 'beyond the end of the clinical trial. For SAEs which have stabilised and cannot be expected to', 'resolve during the trial or the safety follow-up periods, for example chronic or stabilised', 'conditions, \"not resolved\\' is accepted as a final outcome and a statement that the SAE has', 'stabilised or is chronic should be added to the narrative in the SAE form.', '13.8 Handling of an urgent safety measure', 'An urgent safety measure is a measure taken to implement an action/protocol deviation under', 'an', 'emergency. This is defined as \" the occurrence of any new event relating to the conduct', 'of the trial or the development of the investigational medicinal product where that new event', 'is likely to affect the safety of the subjects, the sponsor and the investigator shall take', 'appropriate urgent safety measures to protect the subjects against any immediate', 'hazard.\" (22).', 'If the investigator becomes aware of information that necessitates an immediate change in the', 'clinical trial procedure or a temporary halt to the clinical trial in order to protect clinical trial', 'subjects from any immediate hazard to their health and safety, the investigator can do so', 'without prior approval from LEO, regulatory authorities, or IRBs/IECs.', 'The investigator must immediately inform LEO - by contacting the clinical project manager', 'or', 'medical expert - of this change in the clinical trial procedure or of the temporary halt', 'providing full details of the information and the decision making process leading to the', 'implementation of the urgent safety measure.', 'LEO must act immediately upon receipt of the urgent safety measure notification in', 'accordance with internal procedures and local legislation.']\n\n###\n\n", "completion": "END"}